Drug Trial Radar · NCT07786454
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,120
Planned (sponsor's estimate)
Start
Oct 8, 2026
Primary completion
May 26, 2029
Study completion Jun 2, 2029
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Aug 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult participants with generalized anxiety disorder (GAD) over a treatment period of 26 weeks.
Conditions
- Generalized Anxiety Disorder
Interventions
SEP-363856Drug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to DiscontinuationTime frame: Throughout the trial (up to Week 27)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Neuroscience Solutions, LLC
Jacksonville, Florida · Recruiting
Clinical Neuroscience Solutions Inc. (CNS) - Orlando
Orlando, Florida · Recruiting
Basil Clinical
Jamaica, New York · Recruiting
Manhattan Behavioral Medicine PLLC
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.